Summary by Futu AI
180 Life Sciences Corp. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 15, 2024, for the issuance of common stock shares. The registration statement includes a prospectus for the resale of up to 1,900,138 shares of common stock by the selling stockholder, Armistice Capital, LLC. These shares are issuable upon the exercise of warrants acquired by the selling stockholder under an inducement agreement. The company will not receive any proceeds from the sale of shares by the selling stockholder. However, if all warrants are exercised for cash, 180 Life Sciences may receive up to approximately $2,850,207, which it intends to use for operationalizing and developing its recently acquired Technology Gaming Platform, and for general corporate and legal expenses. The common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'. The company has also detailed its capital structure, including its authorized common and preferred stock, and outlined certain anti-takeover provisions in its certificate of incorporation and bylaws.